Background: On the basis of clinical activity of capecitabine and gemcitabine for metastatic breast cancer, we carried out a multicenter phase II clinical trial on the combination of these two agents in advanced anthracyclinepretreated breast cancer patients. Main objectives were to assess its efficacy and safety profile. Results: Overall response rate was 61% for group-1, 48.5% for group-2 and 55.2% for the whole population. Clinical benefit rate was 73% for group-1, 80% for patients in group-2 and 76% for all patients. Median time to progression was 13.0 months for group-1, 8.2 months for group-2 and 11.1 months for the whole population. Most frequent grade 3-4 observed toxic effects per patient were neutropenia (60%), asymptomatic liver toxicity (13.5%), asthenia (14%) and hand-foot syndrome (16%). Only one patient presented febrile neutropenia. No treatment-related deaths occurred.
introduction
Anthracyclines are still the cornerstone of the antineoplastic treatment of breast cancer, as they have been for >30 years. Earlier use of anthracycline-based chemotherapy, in the continuum from early stage to advanced stage, is increasing in the treatment of breast cancer patients. As a consequence, prior treatment with anthracyclines is currently a common situation when deciding the best treatment option for advanced breast cancer patients, and new therapeutic agents or combinations are clearly needed in this setting.
It is well known that the efficacy of antineoplastic treatments decline over subsequent lines of therapy mainly due to mechanisms of multidrug resistance; this paradigm is a stimulus for investigators to carry out clinical trials in the setting of anthracycline or anthracycline-taxane previously exposed breast cancer. In many countries, taxanes have constituted the preferred treatment of anthracycline-pretreated breast cancer patients; other agents such as vinorelbine, 5-fluorouracil, capecitabine or gemcitabine are also used. Combining different chemotherapies, looking for an additive or synergistic effect, is a well-known strategy to improve the efficacy of antineoplastic treatments, and it would be a good option for advanced pretreated breast cancer patients. This approach could be obscured by additive toxic effects, that is, the reason for the relevance of finding combinations of chemotherapeutic agents with a good toxicity profile.
Capecitabine is an orally administered prodrug of the fluoropyrimidine 5-fluorouracil. It is converted to its active form by thymidine phosphorylase, enzyme that is found in higher concentrations in tumor tissues than in normal host tissues. Capecitabine was initially developed for treating colorectal and breast cancer, but it is currently used in many cancer types. Capecitabine monotherapy has shown response rates ranging between 25% and 37% in first-line treatment of original article advanced breast cancer [1, 2] and from 9% to 53% in several phase II studies [3] in patients previously treated for advanced disease. Gemcitabine is a pyrimidine analogue of deoxycytidine, which is used as a standard treatment in many tumors such as pancreatic, bladder and non-small-cell lung cancer. Efficacy of gemcitabine alone in breast cancer patients has been evaluated in prior phase I-III clinical trials [4] [5] [6] : overall, response rates vary from 14% as monotherapy up to 82% in three-drug combinations [7] [8] [9] [10] . Toxicity is mild (mainly asthenia and hematological) and the treatment is, in general, well tolerated. Of note, no chronic significant toxic effects, especially no chronic cardiotoxicity, have been observed associated to capecitabine and to gemcitabine. Preclinical studies have shown that gemcitabine has a synergistic effect when combined with capecitabine in vivo [11] . On the basis of these data, this combination has been tested in four phase I clinical trials [12] [13] [14] [15] , that showed that the hematological adverse events were the dose-limiting toxicity. Several phase II clinical trials have demonstrated the feasibility of this combination, with a mild toxicity and promising efficacy in a wide range of solid tumors, such as advanced pancreatic cancer [16] . There are previous reported series of advanced breast cancer patients who have been treated with the combination of capecitabine plus gemcitabine. In a retrospective review of 31 patients previously treated with anthracyclines and taxanes, overall response rate was 10% and median time to progression was 6 months [17] . In another prospective phase II trial of this combination in 39 patients with advanced breast cancer pretreated with anthracyclines and taxanes, overall response rate was 48.7% and median time to progression was 5 months [18] .
In summary, preclinical data showed synergistic activity between gemcitabine and capecitabine, and clinical data showed activity in advanced breast cancer for both gemcitabine and capecitabine as monotherapy. In addition, phase I and II trials of the combination have shown a good toxicity profile and have established its feasibility. With this background, we decided to carry out a phase II clinical trial of this combination in advanced, anthracycline-pretreated, breast cancer patients.
patients and methods

patient selection
Main inclusion criteria were as follows: female, >18 years, histologically proven advanced breast cancer, Eastern Cooperative Oncology Group performance status (0-2), measurable disease according to the RECIST criteria [19] and adequate bone marrow, liver and renal functions. Patients were also required to have been previously exposed to almost one anthracycline-based chemotherapy regimen (in the adjuvant, neoadjuvant or advanced setting) and they could be either previously untreated or previously treated (with no more than two previous chemotherapy lines) for advanced disease. A negative pregnancy test at inclusion was required for women with childbearing potential.
Protocol study was approved by the institutional review board of participating centers. The study was conducted according to the Declaration of Helsinki (Washington-2002 version) and following Good Clinical Practice Guidelines. All patients gave written informed consent before enrollment.
study design and objectives
This study was designed as an open-label, multicenter, nonrandomized, single-arm phase II clinical trial. It was preplanned to analyze the data in two different groups, as well as in the whole population. In order to do so, stratification into two groups (groups 1 and 2) was carried out according to patients who have been previously treated for advanced breast cancer (group-2) versus not (group-1). Prior treatment with radiotherapy, trastuzumab or other biological agents, as well as with hormonal therapy were allowed if indicated.
The main objective of this study was to assess overall response rate for the combination of capecitabine and gemcitabine in this population, and secondary objectives were to assess time to progression, duration of response and safety.
statistical methods
Regarding the sample size calculation in group-1, in order to test the null hypothesis of a true response rate of 25% against the alternative hypothesis of a true response rate of almost 50%, 39 assessable patients had to be included (a = 0.05; b = 0.8). A first step of 19 patients enrolled, with a minimum of 6 responders, was considered necessary to continue enrollment in this group. In group-2, in order to test the null hypothesis of a true response rate of 20% against the alternative hypothesis of a true response rate of almost 40%, 33 assessable patients had to be included (a = 0.05; b = 0.8). A first step of 18 patients enrolled, with a minimum of 4 responders, was considered necessary to continue enrollment in this group. Kaplan-Meier actuarial method was used to estimate time to progression, response duration and stabilization duration. Statistic analysis was carried out with SPSS version 13.
treatment plan
Study treatment was a combination of gemcitabine and capecitabine administered on an outpatient basis. On the basis of results of a prior phase I study of the combination [12] , gemcitabine was administered at 1000 mg/m Compliance of capecitabine treatment was assessed with a self-completed treatment diary. Assessable patients had to receive a minimum of three cycles. Treatment continued until progression, unacceptable toxicity, patient's decision or justified physician's decision.
response and toxicity assessments
Tumor response was assessed following the RECIST criteria [19] . Stable disease was defined as less than a 50% reduction and less than a 25% increase in the sum of the products of two perpendicular diameters of all measured lesions and the appearance of no new lesions. Tumor control rate was calculated as the sum of overall response rate plus stable disease rate (defined as stable disease for at least 3 months). Toxicity was evaluated following the National Cancer Institute-Common Toxicity Criteria, version 2.0. Median duration of response of the overall population was 13.6 months: 14.4 months for group-1 and 11.9 months for group-2.
With a median follow-up of 11.4 months (0.23-41.7) at the time of this analysis, 66 patients (86.8%) have progressed or died: 32 patients in group-1 and 34 patients in group-2. Median time to progression was 11.1 months in the whole population: 13 months for patients in group-1 and 8.8 months for patients in group-2. A summary of efficacy results is shown in Table 2 .
overall survival
Median overall survival has not been reached at the time of this analysis, with just six events (7.9%) in the whole patient population.
adverse events
A total of 76 patients were assessable for toxicity. Overall, nonfebrile neutropenia, anemia, asthenia, hand-foot syndrome, liver toxicity and stomatitis were the most common adverse events, although usually mild intensity and reversible. Considering only grade 3-4 toxicity, nonfebrile neutropenia, asthenia, hand-foot syndrome and asymptomatic transaminitis were the most common adverse events (present in >10% of patients). Tables 3 and 4 summarize treatment-related hematological and non-hematological adverse events, respectively. Only one cycle in one patient in group-1 was complicated with febrile neutropenia (0.15% of the total number of cycles, data not shown). There were six serious adverse events that were related to study treatment: three in group-1 and three in group-2. Ten patients (13.2%), five in each group, were withdrawn due to adverse events. No treatment-related deaths occurred.
dose intensity analysis
Median number of cycles administered per patient was 9 (range 1-28). A total of 143 of 683 administered cycles (20.9%) were delayed, in 37% of the cases due to treatment-derived toxicity (hematological in 23.1% of delayed cycles and nonhematological in 14% of cases). Dose of capecitabine was reduced in 48 of 683 administered cycles (7%), in 83.4% of them due to toxicity (in 29.2% due to hematological toxicity and in 54.2% due to non-hematological toxicity). Dose of gemcitabine was reduced in 271 of 683 administered cycles (39.7%), in 84% of them due to toxicity (in 77.1% due to hematological toxicity and in 7% due to non-hematological toxicity). Most dose reductions of gemcitabine were done on day 8 of cycle, when neutropenia and thrombopenia were more frequent (usually mild and asymptomatic).
The most common reasons for study drug discontinuation were progressive disease (37 patients, 48.7%), followed by patient's decision (15 patients, 19.7%), mostly due to prolonged treatment periods without any adverse events or 
discussion
This study shows that the combination of gemcitabine with capecitabine for the treatment of anthracycline-pretreated advanced breast cancer patients offers a high level of activity in patients not previously treated for metastatic breast cancer, as well as in patients previously treated with one or two prior chemotherapy regimens (including treatment with taxanes). The study design draws conclusions about two different groups of patients, each of which properly sized for phase II clinical trial purposes: patients in first-line treatment (group-1) and previously treated patients (group-2). For these advanced breast cancer patients, the search of combined nontoxic chemotherapy regimens is a major clinical issue [20] . This challenging situation has been approached in several ways in previous studies, one of which is the anthracycline re-treatment with liposomal formulations of doxorubicin, which have a more favorable cardiotoxicity profile. Efficacy of both pegylated and nonpegylated liposomal doxorubicin have been assessed in this setting [21] . Another possible approach is to investigate the results of a non-anthracycline-based chemotherapy regimen. Overall response rates of chemotherapy agents alone and in different combinations in heavily pretreated patients range from 26% to 31% [22] [23] [24] [25] [26] [27] . Results of our study in a similar group of patients (group-2) compare favorably with previous studies, resulting in an overall response rate of 50%. It should be highlighted that the present study is, to our knowledge, the first study to show the efficacy and toxicity results of gemcitabine and capecitabine in combination in a group of patients (group-1) not previously treated for advanced disease. Previous studies offer a wide range of overall response rates in this group of patients (from 30% to 74%). The combination of docetaxel with capecitabine has been the first regimen to show, in a randomized phase III trial, a survival benefit without compromising quality of life [28] in anthracycline-pretreated breast cancer patients, and this combination has been considered as a new standard option for these patients [20] . The present study is a phase II clinical trial and this fact precludes extensive comparisons with the results of previous randomized clinical trials. Nevertheless, we can state that our 62% overall response rate is a promising result and is among the highest response rates reported until now. This activity is supported by a favorable time to progressive disease, with a median of 11.1 months in the overall population, which is longer for first-line-treated patients (13 months) than for second-line-and third-line-treated patients (8.8 months), as expected. Tumor control rate was high in both groups of patients but was even higher in group-2. This finding supports the statement that this combination maintains its efficacy over subsequent lines of therapy.
Safety results should be highlighted and discussed together with the issues related with the selection of the regimen used herein. Several regimens of gemcitabine and capecitabine in combination have been reported before the beginning of our study. We chose a regimen very similar to the one evaluated in the trial of Schilsky et al. [12] . This study concluded that a regimen of capecitabine 830 mg/m 2 b.i.d. for 21 days every 28 days associated with full-dose gemcitabine on days 1, 8 and 15 every 28 days was the recommended dose for phase II evaluation, but 30% of patients treated with this regimen required dose modifications. Moreover, a general concern exists when breast cancer patients are treated at full-dose capecitabine monotherapy (1250 mg/m 2 b.i.d. 14 days every 21 days) because lower dose capecitabine has a more favorable riskbenefit balance [2, 29] . On the basis of these data, a similar 21-day regimen with a slightly inferior dose intensity was selected for the present study. As a matter of fact, observed Table 4 . Non-hematological toxicity (per patient, National Cancer Institute-Common Toxicity Criteria version 2.0) toxicity has been mild and manageable in our study. Although 60% of patients experienced grade 3-4 neutropenia, this fact did not translate into a high incidence of febrile neutropenia: of note, just one episode of febrile neutropenia occurred and one of grade 3 thrombocytopenia. However, it was necessary to reduce gemcitabine doses in a 39.7% of administered cycles, almost always on day 8. The most common non-hematological toxicity was the capecitabine-associated hand-foot syndrome, which, however, did not translate into a significant requirement of capecitabine dose reductions. Our study has two main weak points which should be discussed. First, it is a nonrandomized clinical trial and, as a consequence of this, the results should be considered exploratory. Second, it does not consider the HER2 status of the disease, and does not allow the addition of trastuzumab to the study regimen in patients carrying HER2-positive tumors, who accounted a 21% of the study population (in additional 28.9% cases, HER2 status was unknown). Of these 16 patients with overexpression of HER2/neu, 10 patients (treated in group-2) had previously received trastuzumab therapy for advanced disease. Nevertheless, the omission of trastuzumab from the treatment of advanced disease, as first-line therapy as well as for subsequent lines, could have made our results less optimal than if trastuzumab had been included.
We must compare our results with the ones observed in two similar studies, evaluating the same combination with gemcitabine and capecitabine in anthracycline-exposed advanced breast cancer patients. Patient characteristics in these two studies were similar to the patients in our group-2, maybe because they included a majority of patients who were pretreated with taxanes in addition to anthracyclines. One of them [17] is a retrospective analysis of the results of this regimen in 32 patients, achieving an overall response rate of 36%. However, the retrospective nature of this study precludes formal and extensive comparisons with the present study. The second study [18] is a phase II prospective clinical trial including 39 patients heavily pretreated (almost all patients were exposed to both anthracycline and taxanes and more than half to vinorelbine). With a favorable toxicity profile, results of this study showed an overall response rate of 49%, very close to the 50% overall response rate in our group-2 of pretreated patients. This study reports a time to progression of 5 months, much shorter when compared with the 8 months achieved in the present study for the second-line-and third-line-treated patients.
The convenience of the use of gemcitabine as a treatment of advanced breast cancer patients has been criticized in a systematic review [30] . This review concluded that in the second-line setting for heavily pretreated patients, gemcitabine should be used in combination with a taxane. Thus, the results of the present study, together with the previous gemcitabinecapecitabine phase II clinical trials [17, 18] , open the door to find a new combination regimen for the treatment of advanced anthracycline-pretreated breast cancer patients. In addition, using a non-taxane-based combination regimen is a provocative approach, which has the advantage of its potential application in patients who have already received taxanes in the adjuvant setting, as well as in cases in which taxane-derived toxic effects are not allowed (prior neuropathy, patient's denial for alopecia, etc).
In summary, the results of the present study support further investigation of the gemcitabine-capecitabine combination regimen in anthracycline-exposed breast cancer patients. The high level of efficacy and an excellent tolerability make this combination a recommended option for the treatment of firstline to third-line advanced breast cancer patients. 
